HLB Genex (ex-GenoFocus)
GenoFocus 是一个微生物组治疗平台公司：识别后生元（postbiotics）效应分子以发现候选新药，通过强化菌株生产 SOD、芽孢等效应分子开发生物药，针对肠道微生物组失衡恢复肠道健康（人体 98% 的微生物组位于肠道）；与顶级大学医院、研发中心和政府机构合作，推进精准微生物组治疗管线。同时以环保工艺从事特种食品、生物制药、药妆、农业等领域的酶方案业务：酶产品经智能文库分子进化和基于微生物展示的高通量筛选开发，以真菌和细菌分泌系统进行大规模发酵及下游工艺的定制生产。
简介
HLB Genex, Inc. (HLB-acquired former Genofocus in 2024) develops and produces customized industrial enzymes and bio-healthcare materials, including microbiome-enzyme products, using microbial display (surface expression for rapid screening) and recombinant protein expression/secretion (scalable production). Founded 2000-04-01 as Genofocus spin-off; HQ: Techno 1-ro 65, Yuseong-gu, Daejeon, South Korea. Core products: Lactazyme B (lactase/GOS), Katalase (catalase), Proteinase K, plus microbial SOD and several other enzyme platforms. Ownership/stock: HLB Group affiliates acquired 26.48% of Genofocus (KOSDAQ-listed) to gain management control (80B KRW total investment). Latest (2025-2026): Q1 2026 revenue 11.7B KRW, operating profit 1.0B KRW, still active. In 2025 it merged Biomlo g (effective 2025-04-01). Partners/customers include TSMC and other industrial clients (industrial enzyme supply).
Sources#
- 분 기 보 고 서 — 2026-05-14
- HLB Genex Posts 11.7 Billion Won in Q1 Sales, 1.0 Billion Won in Operating Profit…Profitability Trend Continues - The Asia Business Daily — 2026-05-14
- HLB Genex Achieves 35.4 Billion KRW Revenue, Driven by Strong Enzyme Demand < Health < IT Wellness < 기사본문 - IT Times — 2025-03-14
- HLB acquires controlling stake in top domestic enzyme producer - The Korea Times — 2024-10-29
- HLB Genex, Inc.
- HLB Group acquires enzyme producer GenoFocus < Pharma < Article - Korea Biomedical Review — 2024-10-29
- HLB Genex Pushes Antioxidant Enzyme Brand Into Southeast Asia - Seoul Economic Daily — 2026-09-06
- IR/PR | HLB Genex, Inc.
供应的生物解决方案 2
产品与服务
产品: Lactase; Catalase; Proteinase K
- 产品（官网）
- Lactase — World-class enzyme used for producing GOS · Catalase — Enzyme for eco-friendly decomposition of hydrogen peroxide to water and oxygen · Proteinase K — Enzyme used in molecular diagnosis and genetic engineering research - A key enzyme for COVID-19 test kit · Proteinase K — Enzyme used in molecular diagnosis and genetic engineering research. A key enzyme for COVID-19 test kit.
摘自公司官网: home · leadership · topic
新闻与状态 6
- 2024-12, 2025-04 最新状态: 公司于2024年12月由 GenoFocus 更名为 HLB Genex，并于2025年4月吸收合并 BiomeLogic。 ↗ ↗ ↗
- 2026-08-13 HLB제넥스, 상반기 매출 230억…건기식·효소 성장에 11%↑HLB제넥스 (formerly GenoFocus) 보고서는 상반기에 매출이 전년 대비 11% 증가해 230억원을 기록했고, 건강기능식품과 효소 부문이 고르게 성장했다. 특히 카탈라아제와 UDCAse 등 효소 부문이 신규 매출원을 안정적으로 자리잡으며 이익 흐름도 흑자를 지속했다.
- 2026-09-06 HLB Genex Pushes Antioxidant Enzyme Brand Into Southeast Asia - Seoul Economic DailyHLB Genex (formerly GenoFocus) is accelerating its shift from industrial enzymes to healthcare and bio-materials, using its SODyZYM antioxidant enzyme brand to expand in Asia (Taiwan, Thailand, Vietnam, Indonesia) and into eye/skin health products, with a …
- 2026-09-16 HLB Genex Partners with Dongguk University for Regulatory Science Collaboration to Enhance Global Approval Competitiveness - The Asia Business DailyHLB Genex (formerly GenoFocus) has signed an MOU with Dongguk University to jointly advance regulatory science, enhancing global approval strategies and commercialization for its specialized enzymes and bio-materials through industry-academia collaboration. …
- 2026-03-24 적자 고리 끊은 HLB제넥스...김의중 대표 "특수 효소·건기식 B2C사업으로 성장 가속"HLB제넥스 (formerly GenoFocus/GenoFocus) has transitioned from a enzyme-focused biotech to a bio-healthcare materials and solutions company under HLB Group, expanding into B2C with probiotic-based health functional foods (SOD-based brand Sodion) and diversifying …
- 2026-04-29 HLB Genex Teams Up With Cosmax to Develop Enzyme-Based K-Beauty Ingredients - Seoul Economic DailyHLB Genex is expanding from industrial enzymes into the beauty ingredient sector by partnering with Cosmax Group to develop enzyme-based, eco-friendly cosmetic ingredients and establish mass production and formulation/development capabilities. The …
- 2026-05-14 HLB Genex Sustains Operating Profit on Subsidiary Sales Growth - Seoul Economic DailyHLB Genex, formerly GenoFocus, sustained its operating profit in Q1 2026 driven by stronger subsidiary performance (GF Fermentech up >26% y/y, led by phytosphingosine and vitamin K2) and a diversified enzyme portfolio, with revenue 11.7B won and operating …
关系网络：股东、合作伙伴、同类
股权与投资方 1
| 母公司 | HLB Group |
合作与交易 3
| 交易对手 | HLB (parent company) …The company changed its name from GenoFocus to HLB Genex in December 2024 and absorbed BiomeLogic in April 2025.… |
| 交易对手 | BiomeLogic (absorbed subsidiary) …The company changed its name from GenoFocus to HLB Genex in December 2024 and absorbed BiomeLogic in April 2025.… |
| 生产合作伙伴 | NPY …gosine (NPY).
- Custom protein development and manufacturing: CDMO services with in-house contract manufacturing facilities for new protein development.
In short, the company offers specialized enzy… |
同类企业
Amano Enzyme · Dovoy · VTR Biotech · Qingdao Vland Biotech Group Co., Ltd. · Advanced Enzyme Technologies Limited · Kikkoman Biochemifa Co.(Diagnostic Enzymes ) · S.I. Biozyme · Angel yeast
身份与联系方式
联系方式、人员和法律信息仅向会员开放。
会员登录